Vaccine protects against prostate cancer in mice
2 shots stopped disease in rodents with pre-cancerous legions, study
says
updated 3:39 p.m. ET, Wed., Feb. 13, 2008
NEW YORK - An experimental vaccine can provide long-term protection
against prostate cancer in mice genetically predisposed to the
disease, new research indicates.
"By early vaccination, we have basically given these mice life-long
protection against a disease they were destined to have," senior
investigator Dr. W. Martin Kast, from the University of Southern
California in Los Angeles, said in a statement.
"This has never been done before and, with further research, could
represent a paradigm shift in the management of human prostate
cancer."
The vaccine stimulates an immune response against PSCA, which stands
for prostate stem cell antigen. PSCA is a good vaccine target because
it is overly expressed in prostate cancer, but displays limited
expression in other tissues, the investigators note.
In the new study reported in the journal Cancer Research, the
investigators administered a PSCA-based vaccine to mice made prone to
prostate cancer. The animals were 8 weeks old and already had pre-
cancerous prostate lesions.
Vaccination was associated with a robust immune response. At 12
months, 90 percent of the vaccinated mice were still alive, while all
of the control animals had either died or had large tumors.
Human studies are needed to confirm the safety and efficacy of this
vaccine strategy. "We feel this is a very promising approach. With
just two shots, the vaccine will prime immune cells to be on the
lookout for any cell that over-expresses
PSCA."http://www.msnbc.
--
Vaccine protects against prostate cancer in mice
NEW YORK (Reuters Health) - An experimental vaccine can provide long-
term protection against prostate cancer in mice genetically
predisposed to the disease, new research indicates.
"By early vaccination, we have basically given these mice life-long
protection against a disease they were destined to have," senior
investigator Dr. W. Martin Kast, from the University of Southern
California in Los Angeles, said in a statement.
"This has never been done before and, with further research, could
represent a paradigm shift in the management of human prostate
cancer."
The vaccine stimulates an immune response against PSCA, which stands
for prostate stem cell antigen. PSCA is a good vaccine target because
it is overly expressed in prostate cancer, but displays limited
expression in other tissues, the investigators note.
In the new study reported in the journal Cancer Research, the
investigators administered a PSCA-based vaccine to mice made prone to
prostate cancer. The animals were 8 weeks old and already had pre-
cancerous prostate lesions.
Vaccination was associated with a robust immune response. At 12
months, 90 percent of the vaccinated mice were still alive, while all
of the control animals had either died or had large tumors.
Human studies are needed to confirm the safety and efficacy of this
vaccine strategy. "We feel this is a very promising approach. With
just two shots, the vaccine will prime immune cells to be on the
lookout for any cell that over-expresses
PSCA."
SOURCE: Cancer Research, February 1, 2008.
http://www.sciam.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment